Kinetics of maternally derived antibodies upon intramuscular vaccination against classical swine fever with Suvaxyn CSF Marker (CP7_E2alf).

Classical swine fever (CSF) remains one of the most important viral diseases that impact on sustainable pig production world wide. To control the disease in either endemic situations or in case of large, high-impact contingencies, safe and highly efficacious live attenuated vaccines exist since decades. However, until recently, the available live vaccines did not allow a serological marker concept that would be important to circumvent long-term trade restrictions. Recently, a new live attenuated marker vaccine, Suvaxyn CSF Marker (Zoetis), was licensed by the European Medicines Agency (EMA). To supplement the data that are necessary for the design of appropriate vaccination strategies, a trial was carried out with single "emergency-type" vaccination of two pregnant sows. Focus was laid on the kinetics of maternally derived antibodies (MDA) in the screening assays of their offspring that would be used in case of a CSF outbreaks, i.e. CSFV E2 and E antibody ELISA. Neutralization peroxidase linked antibody assays were carried out to allow a rough estimate of protection. Upon vaccination with Suvaxyn CSF Marker 21days before farrowing, MDAs were measurable in all piglets born to the vaccinated sows. The E2 ELISA reactivities showed an almost linear decrease over 10 weeks after which all piglets were tested negative in the ELISA again. No problems were observed in DIVA assays (E antibodies) when heat-inactivated sera were used. The protective effect of MDA needs further investigations as the titers were found to be lower than reported for C-strain vaccines.